Interleukin-6 activity in urine and serum in patients with bladder carcinoma

J Urol. 1992 Sep;148(3):791-4. doi: 10.1016/s0022-5347(17)36721-6.

Abstract

To investigate the correlation between interleukin-6 and urothelial neoplasms, interleukin-6 activities in blood and urine samples of patients with bladder carcinoma were measured with a proliferation assay using an interleukin-6 dependent murine hybridoma clone, MH60.BSF2. A total of 43 patients and 15 normal volunteers were entered into this study. All of the patients were examined preoperatively and 26 were reexamined more than 6 days postoperatively to eliminate the effect of surgical injury on interleukin-6 secretion. The interleukin-6 titers in urine and serum increased in accordance with the progression of the tumor stage, and tumor removal induced a remarkable decrease in the titer of urinary interleukin-6. Although the interleukin-6-producing site has not been elucidated yet, our study suggests that interleukin-6 activity in bladder carcinoma patients may reflect the immunoreaction against the tumor in local urothelium.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Transitional Cell / blood
  • Carcinoma, Transitional Cell / metabolism*
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / urine
  • Female
  • Humans
  • Interleukin-6 / blood
  • Interleukin-6 / metabolism*
  • Interleukin-6 / urine
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Postoperative Period
  • Preoperative Care
  • Urinary Bladder Neoplasms / blood
  • Urinary Bladder Neoplasms / metabolism*
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / urine

Substances

  • Interleukin-6